HTBA Acquires Specnova to Enhance Bioavailability Portfolio, Eyeing EU & US Markets
Barcelona-based HTBA's acquisition of US biotech Specnova signals a strategic move to integrate advanced delivery technologies into its ingredient portfolio, targeting increased bioavailability and market share in functional ingredients across Europe and North America.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Barcelona-based HTBA, a prominent manufacturer of citrus flavonoids and vitamin B12, has acquired US biotech firm Specnova. This strategic move aims to integrate Specnova's expertise in enhancing the bioavailability and efficacy of plant compounds and nutrients into HTBA's existing portfolio, according to NutraIngredients Global. Specnova is recognised for its advanced delivery technologies, specifically Lipovantage and NovaQSpheres, which are designed to improve ingredient stability and absorption.
While both entities will initially operate independently, the long-term objective is to unify their science-backed ingredient offerings. This consolidation will enable a broader range of functional ingredients for customers, focusing on improved performance metrics crucial for differentiating products in competitive markets. The acquisition directly addresses the growing consumer demand for more effective and absorbable supplements, reducing typical dosage requirements or increasing perceived efficacy.
This consolidation offers the combined entity greater leverage in R&D, streamlining the development of cutting-edge delivery solutions. For supplement brand owners, this translates to access to novel ingredient formats that can support stronger efficacy claims and command higher retail prices. Manufacturers will need to evaluate their current product pipelines for potential reformulation opportunities, leveraging these advanced technologies to meet evolving market demands for enhanced nutritional delivery.
What this means for United Kingdom
UK brand owners face a direct competitive imperative to explore advanced delivery systems. Integrating Lipovantage or NovaQSpheres into new product lines could secure a 5-10% premium pricing advantage against standard formats in channels like Boots or Holland & Barrett. Compliance teams must ensure novel ingredient matrices meet FSA novel food regulations, potentially requiring 9-18 months for approval if not previously established. This acquisition offers UK manufacturers opportunities for exclusive ingredient partnerships, securing market differentiation and mitigating supply chain risks associated with single-source botanicals.
The combined operational footprint is expected to yield efficiencies in raw material sourcing and manufacturing scale. This could stabilise or potentially reduce input costs for specific functional ingredients in the medium term, offering a competitive advantage to brands able to quickly adopt these new formulations. Supply chain continuity and intellectual property protection will be key considerations for procurement leads as the integration progresses.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.